Praram 9 Hospital Public Company LimitedReports growth in foreign patients and confident 2026 revenue target.

Praram 9 Hospital, or PR9, said its third-quarter 2026 operating performance is showing growth compared with a year earlier, driven by a rise in foreign patients, especially from the Middle East and Myanmar, as well as more Thai patients returning for treatment. Its second-half strategy is to upgrade care for complex diseases such as kidney disease, heart disease and brain disorders, along with robotic surgery, to attract foreign patients who fly in directly for treatment. Foreign patients currently account for about 27% of the total, with Myanmar and Middle Eastern patients together making up more than half of all foreign patients. The company is confident that 2026 revenue will grow by a single-digit percentage as planned, and is also watching opportunities from Moderna and Merck's mRNA cancer vaccines, as well as government policy that could shift civil servant welfare benefits to a health insurance system, which would create a new customer base for private hospitals.
Praram 9 Hospital Public Company LimitedReports growth in foreign patients and confident 2026 revenue target.
Moderna Inc